Compare ANL & IGR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | ANL | IGR |
|---|---|---|
| Founded | 2004 | 2004 |
| Country | United States | United States |
| Employees | 109 | N/A |
| Industry | | Finance Companies |
| Sector | | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 611.1M | 719.1M |
| IPO Year | 2022 | N/A |
| Metric | ANL | IGR |
|---|---|---|
| Price | $9.36 | $4.62 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $20.00 | N/A |
| AVG Volume (30 Days) | 144.9K | ★ 508.2K |
| Earning Date | 04-10-2026 | 01-01-0001 |
| Dividend Yield | N/A | ★ 13.93% |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $36.02 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.88 | $4.15 |
| 52 Week High | $17.25 | $5.35 |
| Indicator | ANL | IGR |
|---|---|---|
| Relative Strength Index (RSI) | 40.75 | 53.23 |
| Support Level | $9.46 | $4.46 |
| Resistance Level | $9.98 | $4.86 |
| Average True Range (ATR) | 1.35 | 0.07 |
| MACD | 0.05 | 0.01 |
| Stochastic Oscillator | 27.46 | 65.52 |
Adlai Nortye Ltd is a clinical-stage company at the forefront of discovering and developing cancer therapies. The company is building a robust pipeline of drug candidates focused on two key areas where it believes it can make a difference RAS-targeting therapies: its is tackling RAS-driven cancers with AN9025, an oral pan-RAS(ON) inhibitor, and AN4035, a CEACAM5-targeting ADC delivering a potent pan-RAS(ON) inhibitor directly to tumors; Next-generation cancer immunotherapies: its candidates, AN8025 (a tri-functional fusion protein of alphaPD-L1 x CD86 variant x LAG3 variant), a T-cell and antigen-presenting cell modulator, and AN4005 (a first-in-class oral small-molecule PD-L1 inhibitor), are designed to activate cancer immunity in novel ways.
CBRE Clarion Global Real Estate Income Fund is a United States-based diversified, closed-end management investment company. Its primary objective is high current income, and its secondary objective is capital appreciation. The fund invests a majority of its total assets in income-producing real estate securities, which includes common stocks, preferred securities, warrants, and convertible securities issued by real estate companies, such as real estate investment trusts. Under normal market conditions, it invests in real estate equity securities of companies domiciled predominantly in developed countries.